Archives

A valid animal model of SARS-CoV-2 infection and its complications might shed light on the pathophysiology of the disease and can be used for assessing the efficacy and safety of novel antiviral compounds.

At Vibiosphen, we reproduced a mouse model of SARS-CoV-2 infection [1] and modified it to better define key post-infection immunological abnormalities. For this purpose, 7-week-old transgenic (K18-hACE2)2Prlmn male mice were intranasally challenged with a lethal dose (200 PFU/mouse) of SARS-CoV-2 (Wuhan strain).